Dario Contracts With New Employer For Cardiometabolic Solution Beginning In January 2024
Portfolio Pulse from Benzinga Newsdesk
DarioHealth Corp. (NASDAQ:DRIO) has secured a contract to provide its cardiometabolic solution to a national financial and business services company starting January 2024. The solution includes support for diabetes, pre-diabetes, weight management, hypertension, and GLP-1 medication users. Dario's approach combines technology and human support, aiming to improve clinical outcomes through sustained behavior change.
November 27, 2023 | 1:38 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
DarioHealth Corp. has announced a new contract to provide its cardiometabolic health solution to a national employer, which may lead to increased revenue and customer base growth starting January 2024.
The announcement of a new contract for DarioHealth Corp. is a positive development, indicating potential future revenue growth and an expanding customer base. The contract with a national employer showcases confidence in Dario's solutions and may lead to further contracts. The impact is scored as positive, with high relevance due to the direct involvement of the company. The importance is significant as it pertains to future growth, but not at the highest level since the contract starts in 2024. The confidence level reflects the positive nature of the news but accounts for the time until the contract's commencement.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 100